These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Synthesis and evaluation of novel neamine derivatives effectively targeting to RNA. Xu Y; Jin H; Yang Z; Zhang L; Wang Q; Li M; Zhang L Bioorg Med Chem Lett; 2009 Apr; 19(8):2103-6. PubMed ID: 19327991 [TBL] [Abstract][Full Text] [Related]
27. Sample Power and ExpDesign: tools for improving design of animal experiments. van Wilgenburg H; van Schaick Zillesen PG; Krulichova I Lab Anim (NY); 2003 Mar; 32(3):39-43. PubMed ID: 12601388 [TBL] [Abstract][Full Text] [Related]
28. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Baboota S; Shakeel F; Ahuja A; Ali J; Shafiq S Acta Pharm; 2007 Sep; 57(3):315-32. PubMed ID: 17878111 [TBL] [Abstract][Full Text] [Related]
29. Clinical trials with allergen products--statistical considerations. Volkers P Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):172-80; discussion 181. PubMed ID: 17393737 [No Abstract] [Full Text] [Related]
30. Progressive statistics for studies in sports medicine and exercise science. Hopkins WG; Marshall SW; Batterham AM; Hanin J Med Sci Sports Exerc; 2009 Jan; 41(1):3-13. PubMed ID: 19092709 [TBL] [Abstract][Full Text] [Related]
32. Are large trials less reliable than small trials? Rücker G; Schwarzer G; Schumacher M; Carpenter J J Clin Epidemiol; 2009 Aug; 62(8):886-7; author reply 887-9. PubMed ID: 19481419 [No Abstract] [Full Text] [Related]
33. Sample size calculations based on ranking and selection in microarray experiments. Matsui S; Zeng S; Yamanaka T; Shaughnessy J Biometrics; 2008 Mar; 64(1):217-26. PubMed ID: 17680829 [TBL] [Abstract][Full Text] [Related]
34. Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs. Cogger KO J Clin Psychopharmacol; 2007 Aug; 27(4):418-20. PubMed ID: 17632240 [No Abstract] [Full Text] [Related]
35. How I do it: sample size calculations. O'Hara J Clin Otolaryngol; 2008 Apr; 33(2):145-9. PubMed ID: 18429871 [TBL] [Abstract][Full Text] [Related]
36. Exploiting complexity and the robustness of network architecture for drug discovery. Hellerstein MK J Pharmacol Exp Ther; 2008 Apr; 325(1):1-9. PubMed ID: 18202293 [TBL] [Abstract][Full Text] [Related]
37. [Analysis and importance of statistical power and sample size in empirical scientific research]. Klimek KM Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834 [TBL] [Abstract][Full Text] [Related]
38. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Gravel J; Opatrny L; Shapiro S Clin Trials; 2007; 4(4):350-6. PubMed ID: 17848496 [TBL] [Abstract][Full Text] [Related]
39. A small molecule targeting the multifactorial nature of Alzheimer's disease. Cavalli A; Bolognesi ML; Capsoni S; Andrisano V; Bartolini M; Margotti E; Cattaneo A; Recanatini M; Melchiorre C Angew Chem Int Ed Engl; 2007; 46(20):3689-92. PubMed ID: 17397121 [No Abstract] [Full Text] [Related]